In today’s recent session, 4.55 million shares of the Can-Fite Biopharma Ltd ADR (AMEX:CANF) have been traded, and its beta is 1.08. Most recently the company’s share price was $1.64, and it changed around $0.07 or 4.46% from the last close, which brings the market valuation of the company to $16.98M. CANF at last check was trading at a discount to its 52-week high of $4.69, offering almost -185.98% off that amount. The share price’s 52-week low was $1.29, which indicates that the recent value has risen by an impressive 21.34% since then. We note from Can-Fite Biopharma Ltd ADR’s average daily trading volume that its 10-day average is 66850.0 shares, with the 3-month average coming to 181.05K.
Can-Fite Biopharma Ltd ADR stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 2 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended CANF as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight. Can-Fite Biopharma Ltd ADR is expected to report earnings per share of 0 for the current quarter.
Can-Fite Biopharma Ltd ADR (AMEX:CANF) trade information
Instantly CANF has been showing a green trend so far today with a performance of 4.46% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 1.8050 on recent trading dayincreased the stock’s daily price by 9.14%. The company’s shares are currently up 0.93% year-to-date, but still up 16.32% over the last five days. On the other hand, Can-Fite Biopharma Ltd ADR (AMEX:CANF) is 0.62% up in the 30-day period. We can see from the shorts that 0.38 million shares have been sold at a short interest cover period of 1.14 day(s).
The consensus price target as assigned by Wall Street analysts is $10, which translates to bulls needing to increase their stock price by 83.6% from its current value. Analyst projections state that CANF is forecast to be at a low of $10 and a high of $10.
Can-Fite Biopharma Ltd ADR (CANF) estimates and forecasts
The year-over-year growth rate is expected to be 641.84%, up from the previous year.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 48.75%.
CANF Dividends
Can-Fite Biopharma Ltd ADR’s next quarterly earnings report is expected to be released on 2024-Mar-27.
Can-Fite Biopharma Ltd ADR (AMEX:CANF)’s Major holders
Upon looking at major shareholders, 1.60% of them are in the hands of institutional investors. The stock currently has a share float of 1.60%.
